| 1. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R. (2007) Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.. Blood, 110 (6): (2075-83). [PMID:17537993] [10.1021/op500134e] |
| 2. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C et al.. (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.. Breast Cancer Res, 11 (5): (R77). [PMID:19874578] [10.1021/op500134e] |
| 3. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK et al.. (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.. Mol Cancer Ther, 3 (11): (1427-38). [PMID:15542782] [10.1021/op500134e] |
| 4. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T et al.. (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.. J Med Chem, 48 (7): (2388-406). [PMID:15801831] [10.1021/op500134e] |
| 5. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al.. (2010) The landscape of somatic copy-number alteration across human cancers.. Nature, 463 (7283): (899-905). [PMID:20164920] [10.1021/op500134e] |
| 6. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y et al.. (2010) Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.. Proc Natl Acad Sci USA, 107 (25): (11501-6). [PMID:20534551] [10.1021/op500134e] |
| 7. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M. (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.. Cancer Cell, 18 (1): (63-73). [PMID:20609353] [10.1021/op500134e] |
| 8. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.. Cell Cycle, 11 (14): (2756-61). [PMID:22767154] [10.1021/op500134e] |
| 9. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al.. (2012) The requirement for cyclin D function in tumor maintenance.. Cancer Cell, 22 (4): (438-51). [PMID:23079655] [10.1021/op500134e] |
| 10. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al.. (2012) Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.. Cancer Cell, 22 (4): (452-65). [PMID:23079656] [10.1021/op500134e] |
| 11. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. (2013) A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.. Cancer Biol Ther, 14 (7): (597-605). [PMID:23792647] [10.1021/op500134e] |
| 12. Zanardi E, Bregni G, de Braud F, Di Cosimo S. (2015) Better Together: Targeted Combination Therapies in Breast Cancer.. Semin Oncol, 42 (6): (887-95). [PMID:26615133] [10.1021/op500134e] |
| 13. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M et al.. (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.. Lancet Oncol, 16 (1): (25-35). [PMID:25524798] [10.1021/op500134e] |
| 14. Johnston SR. (2015) Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.. J Natl Cancer Inst, 107 (10): (1755-70). [PMID:26251289] [10.1021/op500134e] |
| 15. Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L et al.. (2015) FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.. Clin Cancer Res, 21 (21): (4760-6). [PMID:26324739] [10.1021/op500134e] |
| 16. Porter B. (1983) Primary care pediatrics vs. family practice: a nonissue.. Isr J Med Sci, 19 (8): (736-8). [PMID:6885367] [10.1021/op500134e] |
| 17. Huiling Zhou, Chenxin Duan, Huimin Qin, Chaonan Huang, Jingxuan Hou, Yanming Chen, Jin Zhu, Cangcang Xu, Jian Jin, Tao Zhuang. (2023) Synthesis and structural characterization of a novel palbociclib-kaempferol cocrystal with improved tabletability and synergistic antitumor activity. JOURNAL OF MOLECULAR STRUCTURE, 1281 (135101). [PMID:] [10.1016/j.molstruc.2023.135101] |
| 18. Li Tian, Zhou An-Di, Bai Li-Fei, Zhang Xiao-Yang, Zhou Yu-Ting, Yang Hai-Li, Xu Le-Tian, Guo Xin-Qin, Zhu Xi-Yu, Wang Dong-Jin, Gu Hong-Wei, Wang Xiao-Ming. (2022) Design, synthesis, and anticancer activity of three novel palbociclib derivatives. Frontiers in Oncology, 12 [PMID:36091173] [10.3389/fonc.2022.959322] |
| 19. Chenxin Duan, Wenwen Liu, Yunwen Tao, Feifei Liang, Yanming Chen, Xinyi Xiao, Guisen Zhang, Yin Chen, Chao Hao. (2022) Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate. Pharmaceutics, 14 (1): (23). [PMID:35056919] [10.3390/pharmaceutics14010023] |
D2303098